PDF(Pubmed)
Abstract：
UNASSIGNED: Activation of fibroblast growth factor receptor 1 (FGFR1) signaling improves the metabolic health of animals and humans, while inactivation leads to diabetes in mice. Direct human genetic evidence for the role of FGFR1 signaling in human metabolic health has not been fully established.
UNASSIGNED: We hypothesized that individuals with naturally occurring FGFR1 variants (\"experiments of nature\") will display glucose dysregulation.
UNASSIGNED: Participants with rare FGFR1 variants and noncarrier controls. Using a recall-by-genotype approach, we examined the β-cell function and insulin sensitivity of 9 individuals with rare FGFR1 deleterious variants compared to 27 noncarrier controls, during a frequently sampled intravenous glucose tolerance test at the Reproductive Endocrine Unit and the Harvard Center for Reproductive Medicine, Massachusetts General Hospital. FGFR1-mutation carriers displayed higher β-cell function in the face of lower insulin sensitivity compared to controls.
UNASSIGNED: These findings suggest that impaired FGFR1 signaling may contribute to an early insulin resistance phase of diabetes pathogenesis and support the candidacy of the FGFR1 signaling pathway as a therapeutic target for improving the human metabolic health.
UNASSIGNED: We hypothesized that individuals with naturally occurring FGFR1 variants (\"experiments of nature\") will display glucose dysregulation.
UNASSIGNED: Participants with rare FGFR1 variants and noncarrier controls. Using a recall-by-genotype approach, we examined the β-cell function and insulin sensitivity of 9 individuals with rare FGFR1 deleterious variants compared to 27 noncarrier controls, during a frequently sampled intravenous glucose tolerance test at the Reproductive Endocrine Unit and the Harvard Center for Reproductive Medicine, Massachusetts General Hospital. FGFR1-mutation carriers displayed higher β-cell function in the face of lower insulin sensitivity compared to controls.
UNASSIGNED: These findings suggest that impaired FGFR1 signaling may contribute to an early insulin resistance phase of diabetes pathogenesis and support the candidacy of the FGFR1 signaling pathway as a therapeutic target for improving the human metabolic health.
摘要：
■成纤维细胞生长因子受体1（FGFR1）信号的激活改善了动物和人类的代谢健康，而失活导致小鼠糖尿病。关于FGFR1信号传导在人类代谢健康中的作用的直接人类基因证据尚未完全确定。
■我们假设具有天然存在的FGFR1变体（“自然实验”）的个体将表现出葡萄糖失调。
■具有罕见FGFR1变体和非携带者对照的参与者。使用按基因型召回的方法，与27名非携带者对照相比，我们检查了9名具有罕见FGFR1有害变异的个体的β细胞功能和胰岛素敏感性。在生殖内分泌单位和哈佛生殖医学中心的频繁采样的静脉葡萄糖耐量试验中，马萨诸塞州总医院。与对照组相比，FGFR1突变携带者在胰岛素敏感性较低的情况下表现出更高的β细胞功能。
■这些研究结果表明，受损的FGFR1信号可能有助于糖尿病发病机制的早期胰岛素抵抗阶段，并支持FGFR1信号通路作为改善人类代谢健康的治疗靶标的候选性。
■我们假设具有天然存在的FGFR1变体（“自然实验”）的个体将表现出葡萄糖失调。
■具有罕见FGFR1变体和非携带者对照的参与者。使用按基因型召回的方法，与27名非携带者对照相比，我们检查了9名具有罕见FGFR1有害变异的个体的β细胞功能和胰岛素敏感性。在生殖内分泌单位和哈佛生殖医学中心的频繁采样的静脉葡萄糖耐量试验中，马萨诸塞州总医院。与对照组相比，FGFR1突变携带者在胰岛素敏感性较低的情况下表现出更高的β细胞功能。
■这些研究结果表明，受损的FGFR1信号可能有助于糖尿病发病机制的早期胰岛素抵抗阶段，并支持FGFR1信号通路作为改善人类代谢健康的治疗靶标的候选性。
